Annals of Oncology 14:242-247, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer
1 Medical Oncology Unit B, 2 Unit of Experimental Oncology C, 3 Unit of Medical Statistics and Biometry, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Received 27 May 2002; revised 9 August 2002; accepted 11 September 2002
Background:
To explore the activity and tolerability of gemcitabine (GEM) and carboplatin (CBDCA) in non-small-cell lung cancer (NSCLC) we tested four administration sequences on H460 NSCLC cells, and at the same time performed a randomized phase II trial using analogous schedules.
Patients and methods:
GEM was given first in two in vitro sequences, and CBDCA first in the other two; interaction was quantified calculating a combination index. Eighty-eight chemotherapy-naïve, stage IV NSCLC patients were randomly assigned to receive either: GEM (1000 mg/m2) on days 1 and 8 and CBDCA (AUC 5 mg·min/ml) on day 1, 4 h before GEM (arm A); same as arm A except CBDCA given 4 h after GEM (arm B); GEM on days 1 and 8 and CBDCA on day 2 (arm C); GEM on days 2 and 9 and CBDCA on day 1 (arm D). Courses were repeated every 21 days.
Results:
In the preclinical study, CBDCA given before GEM produced a synergistic cytotoxic effect. Two complete and 29 partial responses occurred in 86 of 88 treated patients (intention-to-treat analysis 35%; 95% confidence interval 25.5% to 46.8%). One- and 2-year survivals were 44% and 11%, respectively. Grade 3/4 thrombocytopenia occurred in 11%; grade 3/4 neutropenia in 17%; and non-hematological toxicity was insignificant. Median survival was 11 months (range 7–18+), but better in patients receiving CBDCA first (arms A and D) (13 versus 9 months) than in patients receiving GEM first (arms B and C). The response was greater (50% versus 31%) in arm A than in the other arms.
Conclusions:
The CBDCA/GEM combination is safe and active against stage IV NSCLC. Our preclinical and clinical findings suggest that administration of CBDCA before GEM gives the better outcome.
Key words: carboplatin, gemcitabine, non-small-cell lung cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Tarang, A. Sodhi, and P. Chauhan Differential expression of Toll-like receptors in murine peritoneal macrophages in vitro on treatment with cisplatin Int. Immunol., May 1, 2007; 19(5): 635 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Bidoli, N Zilembo, D Cortinovis, L Mariani, L Isa, E Aitini, D Cullura, F Pari, P Nova, M Mancin, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study Ann. Onc., March 1, 2007; 18(3): 461 - 467. [Abstract] [Full Text] [PDF]
|
|